SAB Biotherapeutics (NASDAQ:SABS) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of SAB Biotherapeutics (NASDAQ:SABS) from a strong sell rating to a hold rating in a report released on Monday,Zacks.com reports.

SABS has been the subject of several other research reports. Chardan Capital raised their price target on SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. Rodman & Renshaw reaffirmed a “buy” rating and set a $13.00 price target on shares of SAB Biotherapeutics in a report on Monday. HC Wainwright raised their price target on SAB Biotherapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday. Wall Street Zen downgraded SAB Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of SAB Biotherapeutics in a report on Friday, April 10th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

SAB Biotherapeutics Trading Down 2.7%

NASDAQ SABS opened at $3.62 on Monday. The company has a market cap of $184.44 million, a PE ratio of -1.56 and a beta of 0.55. The company has a current ratio of 9.46, a quick ratio of 9.46 and a debt-to-equity ratio of 0.02. SAB Biotherapeutics has a 12 month low of $1.60 and a 12 month high of $6.60. The stock has a 50 day moving average of $3.86 and a 200-day moving average of $3.81.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.15). On average, equities research analysts anticipate that SAB Biotherapeutics will post -1.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SABS. HB Wealth Management LLC bought a new position in shares of SAB Biotherapeutics in the third quarter worth $618,000. Dimensional Fund Advisors LP bought a new position in shares of SAB Biotherapeutics in the third quarter worth $32,000. ADAR1 Capital Management LLC bought a new position in shares of SAB Biotherapeutics in the third quarter worth $30,000. Virtu Financial LLC bought a new position in shares of SAB Biotherapeutics in the third quarter worth $40,000. Finally, Commodore Capital LP bought a new position in shares of SAB Biotherapeutics in the third quarter worth $8,847,000. Institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.